ASX Announcements

Neuren FDA meeting confirms Phase 3 plan for Rett syndrome
Investor presentation, 6 October 2017
Presentations and publication for Rett syndrome trials
Change of Director's Interest Notice
Change of Director's Interest Notice
Change of Director's Interest Notice
Notice under section 708A(5)(e) of the Corporations Act
Appendix 3B
Results of Meeting
Neuren reports 2017 half-year results